Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 6/20 | 0.41 |
| ▸ | PRKDC | P78527 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29222808 | 0.83 | CA1 (0.43) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL399643 | 0.80 | PTGS2 (0.69) | ALDH1A1HSD17B10PTGS2PTGS1 | |
| SCHEMBL1271133 | 0.80 | ALDH1A1 (0.58) | CA12CA1CA2CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9311376 | 0.79 | PTGS2 (0.67) | ALDH1A1HSD17B10PTGS2PTGS1 | |
| SCHEMBL4861820 | 0.78 | CA2 (0.65) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29964465 | 0.78 | MKNK1 (0.51) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL14519925 | 0.77 | CA12 (0.54) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL10060466 | 0.77 | CA12 (0.46) | CA12CA1CA2CA9ADAMTS4 | |
| SCHEMBL10826584 | 0.77 | ALDH1A1 (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6794414 | 0.76 | LTB4R2 (0.48) | ALDH1A1PTGS2ADAMTS4ATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1910364-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2007011833-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | CA12 3731/4885CA1 1042/4885CA2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.